Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Amanda C. Winters"'
1
Akademický článek
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine
Autor: Amanda C. Winters, Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Grace Bosma, Diana Abbott, Nicholas Miltgen, Ji Yuan, Amy L. Treece, Bradford J. Siegele, Mark D. Ewalt, Jonathan A. Gutman, Craig T. Jordan, Daniel A. Pollyea
Publikováno v: Haematologica, Vol 109, Iss 6 (2023)
Venetoclax with azacitidine (ven/aza) is a lower-intensity therapeutic regimen that has been shown to improve outcomes in elderly patients with acute myeloid leukemia (AML). Measurable residual disease (MRD) using flow cytometry is a valuable tool fo
Externí odkaz: https://doaj.org/article/dd1f3941b21d43f7a99618a3961ccd30
Zobrazit plný text záznamu
2
Akademický článek
Molecular measurable residual disease: staring at red herrings
Autor: Amanda C. Winters, Daniel A. Pollyea
Publikováno v: Haematologica, Vol 109, Iss 2 (2023)
Externí odkaz: https://doaj.org/article/c4874fcfc444493d8047ce88f5a8b478
Zobrazit plný text záznamu
3
Akademický článek
Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells
Autor: Lindsey A. Murphy, Amanda C. Winters
Publikováno v: Biomedicines, Vol 11, Iss 12, p 3248 (2023)
Acute myeloid leukemia (AML) is a rare subtype of acute leukemia in the pediatric and adolescent population but causes disproportionate morbidity and mortality in this age group. Standard chemotherapeutic regimens for AML have changed very little in
Externí odkaz: https://doaj.org/article/8ea1843eaf054dd08613de185b4b329e
Zobrazit plný text záznamu
4
Akademický článek
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia
Autor: Amanda C. Winters, Jonathan A. Gutman, Enkhtsetseg Purev, Molly Nakic, Jennifer Tobin, Stephanie Chase, Jeff Kaiser, Lindsey Lyle, Chelsey Boggs, Keri Halsema, Jeffrey T. Schowinsky, Julie Rosser, Mark D. Ewalt, Bradford Siegele, Vishal Rana, Steven Schuster, Diana Abbott, Brett M. Stevens, Craig T. Jordan, Clayton Smith, Daniel A. Pollyea
Publikováno v: Blood Advances, Vol 3, Iss 20, Pp 2911-2919 (2019)
Abstract: Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients. Venetoclax was available prior to approval off-label. We assessed our single-institution off-label experience with venetoclax/azacitidine, comparing outcomes
Externí odkaz: https://doaj.org/article/1934278e1f804e4f9fde48ee8377753e
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje